Research programme: Neurological disorders therapeutics - Asceneuron

Drug Profile

Research programme: Neurological disorders therapeutics - Asceneuron

Alternative Names: ASN 120290; ASN-561

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer Asceneuron
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Hexosaminidase C inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 06 Apr 2017 Asceneuron announces regulatory approval of its CTA to initiate a phase I safety trial of ASN 120290
  • 06 Apr 2017 Asceneuron plans a proof-of-concept phase II trial for Progressive supranuclear palsy (In the elderly) (PO)
  • 06 Oct 2016 Preclinical development is ongoing for Alzheimer's disease in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top